Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT

NCT03809481 is registered in ClinicalTrials.gov with Aspen Global Incorporated as lead sponsor.

NCT NCT03809481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03809481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT
Lead sponsor
Aspen Global Incorporated
Phase
Phase 3
Overall status
Terminated
Start date
May 16, 2019
Completion date
June 10, 2022
Enrollment
7 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

heparin-induced thrombocytopenia